Seminoma medical therapy

Jump to navigation Jump to search

Seminoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Seminoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

TNM
Stage Grouping

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Treatment - Stage I
Treatment - Stage II
Treatment - Stage III
Treatment - Recurrent

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Seminoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Seminoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Seminoma medical therapy

CDC on Seminoma medical therapy

Seminoma medical therapy in the news

Blogs on Seminoma medical therapy

Directions to Hospitals Treating Seminoma

Risk calculators and risk factors for Seminoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

  • Treatments of patients with seminoma depends on stage of seminoma, risk of recurrence, Fertility and Preferences of the individual. The majority of patients with seminoma are treated Chemotherapy. Chemotherapy is helpful for all stages of seminoma. Chemotherapy is used in patients who have done orchiectomy. A combination of chemotherapy drugs is usually given. Seminoma is a radiosensitive tumor. Radiation therapy may be helpful to treat stage I or II seminomas after orchiectomy. Active surveillance is the preferred treatment for stege I seminoma after a radical inguinal orchiectomy. There are no standard active surveillance schedules for seminoma. There are no standard active surveillance schedules for seminoma.

Medical Therapy


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of Seminoma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage I
 
 
 
Stage II
 
 
 
 
 
Stage III
 
 
 
Recurrent
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surgery
❑ Active surveillance
Radiotherapy
Chemotherapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Chemotherapy

Radiotherapy

Active Surveillance

  • Active surveillance is the preferred treatment for stage I seminoma after a radical inguinal orchiectomy.
  • During active surveillance, the healthcare team watches for any signs and symptoms of recurrence. Treatment is given only if seminoma recurs.
  • There are no standard active surveillance schedules for seminoma. Active surveillance may last for 5-10 years. You may have follow-up visits every 2-6 months for the first 3 years.

References

  1. Cullen, M. (2012). "Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours". Annals of Oncology. 23 (suppl 10): x342–x348. doi:10.1093/annonc/mds306. ISSN 0923-7534.
  2. Sagalowsky AI (October 2000). "Treatment options for clinical stage 1 testis cancer". Proc (Bayl Univ Med Cent). 13 (4): 372–5. PMC 1312235. PMID 16389345.
  3. Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A (August 2011). "Pure seminoma: a review and update". Radiat Oncol. 6: 90. doi:10.1186/1748-717X-6-90. PMC 3163197. PMID 21819630.
  4. Ahmed KA, Wilder RB (2015). "Stage IIA and IIB testicular seminoma treated postorchiectomy with radiation therapy versus other approaches: a population-based analysis of 241 patients". Int Braz J Urol. 41 (1): 78–85. doi:10.1590/S1677-5538.IBJU.2015.01.11. PMC 4752059. PMID 25928512.
  5. Lieng H, Warde P, Bedard P, Hamilton RJ, Hansen AR, Jewett M, O'malley M, Sweet J, Chung P (February 2018). "Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach". Can Urol Assoc J. 12 (2): 59–66. doi:10.5489/cuaj.4531. PMC 5937398. PMID 29381453. Vancouver style error: initials (help)
  6. Lodi D, Iannitti T, Palmieri B (January 2011). "Stem cells in clinical practice: applications and warnings". J. Exp. Clin. Cancer Res. 30: 9. doi:10.1186/1756-9966-30-9. PMC 3033847. PMID 21241480.

Template:WH Template:WS